What's more, the survival of XRCC9 was only associated with grade III patients, which showed a favorable PFS and OS in grade III ovarian carcinoma patients (PFS: HR=0.73 (0.62-0.86), P=0.0002, OS: HR=0.74 (0.62-0.87), P=0.0003). The gene discussed is FANCG; the disease is ovarian carcinoma.